Cancer Therapy News and Research

RSS

Millions of cancer survivors are parenting young children, says Wake Forest researcher

In the first ever published estimate of the percentage and number of cancer survivors who live with their minor children, a team led by a Wake Forest University Baptist Medical Center researcher found that millions of cancer survivors are parenting young children, highlighting a group of survivors with very special needs.

29 Jun 2010

APP to market Anastrozole 1 mg tablets in U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

MagForce's Nano-Cancer therapy receives European regulatory approval

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

28 Jun 2010

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Cancer Research UK scientists have discovered certain ovarian tumour cells that are resistant to chemotherapy can survive a first round of treatment and go on to "re-grow" the cancer. This could help explain why the disease can be difficult to treat, according to new research published in Oncogene today (Monday).

28 Jun 2010

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

Experts to meet in Miami to discuss new ways of avoiding errors in radiation therapy

A meeting in Miami this week will bring together some of the world's leading experts from inside and outside the clinic to discuss safety in radiation therapy -- a critical method for treating cancer.

25 Jun 2010

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

Today a group of cancer patients, oncologists, oncology nurses and practice administrators will meet with Members of Congress to speak out about the enormous burden placed by the massive Medicare cuts to U.S. cancer care, and to offer solutions.

24 Jun 2010

UNC team provides first example of successful radiomitigation in mammals

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells.

24 Jun 2010

Hoag Hospital launches IORT program for breast cancer treatment

Hoag Hospital announced the launch of its Intraoperative Radiation Therapy program as part of its progressive, comprehensive approach to breast cancer treatment. IORT is a radiation therapy technique in which a concentrated dose of radiation is delivered to a cancerous tumor site during surgery after the tumor is removed. Hoag Hospital is the first in Orange County to offer IORT brachytherapy for breast cancer as a component of a definitive treatment approach.

24 Jun 2010

New poll illustrates difficult situations cancer patients face in affording needed health care

A new poll illustrates the difficulty that cancer patients, survivors and their families face in affording needed health care and paying for other basic necessities such as food and heat, underscoring the need to strongly implement the Affordable Care Act so that it works for people with cancer.

24 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will add two new centers to its extensive network by furthering its partnership with the PLA Navy General Hospital, located in Beijing.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

22 Jun 2010

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

Hyundai Hope on Wheels, a partnership of Hyundai dealers across the U.S. and Hyundai Motor America, today announced a new nationwide initiative to raise funds to fight childhood cancer. Hyundai dealers have pledged to donate a total of $3 million dollars to Hope on Wheels based on vehicles sold during the month of September (National Childhood Cancer Awareness Month).

19 Jun 2010

Cancer Therapy News and Research

Millions of cancer survivors are parenting young children, says Wake Forest researcher

APP to market Anastrozole 1 mg tablets in U.S.

Lead researchers develop a novel technique to deliver cancer drugs

MagForce's Nano-Cancer therapy receives European regulatory approval

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Experts to meet in Miami to discuss new ways of avoiding errors in radiation therapy

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

UNC team provides first example of successful radiomitigation in mammals

Hoag Hospital launches IORT program for breast cancer treatment

New poll illustrates difficult situations cancer patients face in affording needed health care

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

UK cancer survival rates increase at 3% each year

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Concord Medical adds two new centers by furthering partnership with Navy General Hospital

Biodesix awarded US patent for VeriStrat serum test

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News